Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | PPARG | P37231 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | ACE | P12821 | 4/20 | 0.63 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.62 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.62 |
| ▸ | ITGAL | P20701 | 2/20 | 0.62 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.61 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1231823 | 1.00 | MEN1 (0.78) | MEN1KMT2AHCRTR1KDM4EALDH1A1 | |
| SCHEMBL29869259 | 0.93 | KMT2A (0.69) | MEN1KMT2AHCRTR1KDM4EALDH1A1 | |
| SCHEMBL1233499 | 0.93 | KMT2A (0.68) | MEN1KMT2AHCRTR1KDM4EALDH1A1 | |
| SCHEMBL1233383 | 0.93 | KMT2A (0.68) | MEN1KMT2AHCRTR1KDM4EALDH1A1 | |
| SCHEMBL31520093 | 0.91 | PPARG (0.70) | MEN1KMT2AHCRTR1KDM4EPPARG | |
| SCHEMBL19051474 | 0.91 | PPARG (0.70) | MEN1KMT2AHCRTR1KDM4EPPARG | |
| SCHEMBL19051488 | 0.89 | PPARG (0.66) | MEN1KMT2AHCRTR1PPARGALOX15 | |
| SCHEMBL31036095 | 0.89 | MEN1 (0.66) | MEN1KMT2AHCRTR1KDM4EPPARG | |
| SCHEMBL21001415 | 0.89 | MEN1 (0.66) | MEN1KMT2AHCRTR1KDM4EPPARG | |
| SCHEMBL21001416 | 0.89 | MEN1 (0.66) | MEN1KMT2AHCRTR1KDM4EPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105572-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2011-05-05 | — | — | US | disclosed |
| US-20110105572-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2011-05-05 | — | — | US | disclosed |
| US-20110105572-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2011-05-05 | — | — | US | disclosed |
| US-7880020-B2 | e.g trichlorostatin A; antiproliferative agent; for treating cancer and psoriasis | TOPOTARGET UK LIMITED (GB) | 2011-02-01 | — | — | US | disclosed |
| US-7880020-B2 | e.g trichlorostatin A; antiproliferative agent; for treating cancer and psoriasis | TOPOTARGET UK LIMITED (GB) | 2011-02-01 | — | — | US | disclosed |
| US-7880020-B2 | e.g trichlorostatin A; antiproliferative agent; for treating cancer and psoriasis | TOPOTARGET UK LIMITED (GB) | 2011-02-01 | — | — | US | disclosed |
| US-20100249197-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-09-30 | — | — | US | disclosed |
| US-20100249197-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-09-30 | — | — | US | disclosed |
| US-20100249197-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-09-30 | — | — | US | disclosed |
| US-7569724-B2 | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| US-7569724-B2 | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| US-7569724-B2 | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| EP-2083005-A1 | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors | TopoTarget UK Limited (GB) | 2009-07-29 | — | — | EP | disclosed |
| EP-1598067-A1 | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors | TopoTarget UK Limited (GB) | 2005-11-23 | — | — | EP | disclosed |
| US-20040092598-A1 | Carbamic acid compounds comprising an amide linkage as hdac inhibitors | TOPOTARGET UK LIMITED (GB) | 2004-05-13 | — | — | US | disclosed |
| EP-1335898-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | Prolifix Limited (GB) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002026696-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092598-A1 | Carbamic acid compounds comprising an amide linkage as hdac inhibitors | HDAC1, HDAC11, HDAC3 | MEN1 4378/4885KMT2A 119/4885HCRTR1 351/4885 |
| US-20110105572-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | HDAC1, HDAC7, HDAC5 | MEN1 2598/4885KMT2A 115/4885HCRTR1 323/4885 |
| US-20100249197-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | HDAC1, HDAC11, HDAC3 | MEN1 4123/4885KMT2A 85/4885HCRTR1 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.